Pfizer on Dec. 1 said it will halt the development of its twice-daily version of its experimental weight-loss pill after participants in a midstage clinical study showed high rates of having trouble tolerating the drug.
Pfizer’s drug, called danuglipron, is a GLP-1 receptor agonist that works the same way as weight-loss injections from Novo Nordisk and Eli Lilly, mimicking a hormone that controls feelings of satiety and how fast the contents of the stomach reach the gut. Unlike those drugs, danuglipron comes as an oral tablet, an advantage in convenience that Pfizer hoped could give it a competitive edge in a race to carve up the multibillion-dollar market.
